Sleeve Gastrectomy For Treatment Research Articles

The Role of Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy in Treatment of Type-2-Diabetes Mellitus with Morbid Obesity in Comparison with Mini-Gastric-Bypass

The Role of Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy in Treatment of Type-2-Diabetes Mellitus with Morbid Obesity in Comparison with Mini-Gastric-Bypass

Laparoscopic Sleeve Gastrectomy in Treatment of Morbid Obese child and Adolescent, Single center experience

Laparoscopic Sleeve Gastrectomy in Treatment of Morbid Obese child and Adolescent, Single center experience

Results of sleeve gastrectomy in obese patients with type 2 diabetes mellitus and impaired glucose tolerance: Retrospective cohort registry-based study

Background. In the available literature, the data on the positive effects of sleeve gastrectomy in treatment of type 2 diabetes mellitus (T2DM) and impaired glucose tolerance (IGT) become more common, however, they are heterogeneous and not always unambiguous.The aim. To analyze our own results of treatment of patients with type 2 diabetes mellitus and impaired glucose tolerance, who underwent sleeve gastrectomy.Materials and methods. Retrospective cohort registry-based study was carried out. From 2016 to April 2021, 29 (19 %) and 7 (4.6 %) patients with diagnosed T2DM and IGT respectively underwent surgery. Of these, sleeve gastrectomy was performed in 13 (44.8 %) patients with type 2 diabetes mellitus and in 5 (71.4 %) patients with IGT. The mean duration of follow-up for T2DM and IGT patients was 14.2 ± 12.3 and 11.2 ± 9.0 months respectively.Results. The mean %EWL (% excess weight loss) in patients with T2DM and IGT was 44.1 ± 17.3 and 51.5 ± 16.9 respectively, and the mean %TWL (% total weight loss) was 25.0 ± 8.0 and 27.8 ± 6.0 respectively. At the moment of observation, all patients had normal level of fasting blood glucose. The level of HbA1c in patients with type 2 diabetes before the surgery was 8.2 ± 1.6, after surgery, at the time of observation – 5.8 ± 0.5 (U = 4; p ≤ 0.01). Targeted HbA1c values was recorded in all 13 patients with type 2 diabetes.Conclusion. Our study shows the efficiency of sleeve gastrectomy both in terms of weight loss and of the remission for patients with T2DM and IGT.

Impact of Baseline BMI and Adherence to Follow-Up on the Outcome of Sleeve Gastrectomy in Treatment of Adolescent Obesity.

Adolescent obesity is considered a public health challenge. Sleeve gastrectomy (SG) may be considered a safe option for treatment of adolescent obesity. This study aimed to assess the outcomes of SG in treatment of severe obesity in adolescents, with emphasis on the impact of baseline body mass index (BMI) and adherence to follow-up. This was a single-center retrospective cohort study on adolescents with severe obesity who underwent SG at a tertiary referral bariatric center. The main outcome measures were weight loss, improvement in comorbidities at 12 months postoperatively, and complications. A total of 72 adolescent patients (47 female) of a mean BMI of 47.9 ± 7.1 kg/푚2 were enrolled in the study. The mean %TWL was 34.94 ± 9.35 and the mean %EWL was 73.47 ± 22.12. Complete remission was recorded in all patients with type 2 diabetes mellitus (DM), pre-DM, and sleep apnea, in 80% of patients with hypertension, and 57% of patients with hypothyroidism. The long-term complication rate after SG was 18%. Patients with higher preoperative BMI had significantly (p = 0.018) lower %EWL at 1 year. SG is an effective and safe surgical procedure for adolescents with severe obesity. It was associated with a significant weight loss, high comorbidity remission rates, and no mortality or serious complications. Lower baseline BMI and better adherence to follow-up were associated with better outcome of SG.

The results of Hess–Marceau biliopancreatic diversion with duodenal switch and sleeve gastrectomy in treatment of patients with morbid obesity

The results of Hess–Marceau biliopancreatic diversion with duodenal switch and sleeve gastrectomy in treatment of patients with morbid obesity

Clinical efficacy of the three dimensional laparoscopic sleeve gastrectomy in treatment of obesity combined with type 2 diabetes mellitus

Objective To explore the clinical efficacy of three dimensional (3D) laparoscopic sleeve gastrectomy (LSG) in the treatment of obesity combined with type 2 diabetes mellitus. Methods The retrospective cross-sectional study was conducted. The clinical data of 28 patients with obesity combined with type 2 diabetes mellitus who were admitted to the Qinghai Red Cross Hospital between January 2013 and April 2016 were collected. All the patients underwent 3D LSG. Observation indicators: (1) surgical and postoperative recovery situations; (2) follow-up and metabolic indexes changes. Follow-up using outpatient examination and telephone interview was performed to detect complications of patients after discharge and usages of antidiabetic drugs or insulin up to February 2017. Body mass, body mass index (BMI), hemoglobin (Hb), albumin (Alb), fasting serum C-peptide, fasting blood sugar, 2-hours postprandial blood glucose (2HPBG) and glycosylated hemoglobin (GHb) were detected at month 1, 3, 6 and 12 postoperatively. Measurement data with normal distribution were represented as ±s. Repeated measurement data were analyzed by the repeated measures ANOVA. Count data were evaluated by the proportion. Results (1) Surgical and postoperative recovery situations: 28 patients underwent successful 3D LSG, without conversion to open surgery. Operation time, volume of intraoperative blood loss, time of postoperative gastrointestinal function recovery and time of postoperative drainage tube removal were (133±20)minutes, (45±22)mL, (2.5±1.2)days and (3.4±0.9)days, respectively. There were no postoperative complications and perioperative death. Duration of hospital stay was (7.1±1.5)days. (2) Follow-up and metabolic indexes changes: 28 patients were followed up for 6-12 months, with a median time of 8 months. During the follow-up, there was no death or severe complications. Body mass, BMI, Hb, Alb, fasting serum C-peptide, fasting blood sugar, 2HPBG and GHb from pre-operation to month 1, 3, 6 and 12 post-operatively were decreased from (113±26)kg to (78±14)kg, from (44±6)kg/m2 to (35±5)kg/m2, from (157±19)g/L to (140±13)g/L, from (43±5)g/L to (40±4)g/L, from (2.50±0.37)μg/L to (1.20±0.33)μg/L, from (10.5±2.0)mmol/L to (5.6±0.5)mmol/L, from (16.3±3.1)mmol/L to (7.9±0.9)mmol/L, from 9.2%±0.9% to 6.8%±0.6% with statistically significant differences between preoperative and postoperative indicators (F=396.47, 328.20, 111.10, 21.28, 161.06, 127.80, 243.40, 234.64, P<0.05), and showing a downward trend. Of 28 patients, 25 had complete remission of type 2 diabetes mellitus at 12 months postoperatively and 3 had partial remission, with an effective rate of 100.0%(28/28). The excess weight loss was 63%±16%. Conclusion 3D LSG is safe and effective in the treatment of obesity combined with type 2 diabetes mellitus, with a good short-term outcome. Key words: Obesity; Diabetes mellitus, type 2; Sleeve gastrectomy; Laparoscopy, three dimension

Outcome of Laparoscopic Sleeve Gastrectomy for Treatment Morbidly Obese Patients in Srinagarind Hospital

Background: Laparoscopic sleeve gastrectomy (LSG) has been increasingly popular procedure for treatment morbidly obese patients and showing good weight loss and resolution of comorbidity diseases. The objective of this study was to evaluate postoperative outcome in term of operative complication, weight loss and comorbidity improvement after laparoscopic sleeve gastrectomy. Methods: From July 2011 to December 2014 there is 70 patients (45 woman; 64 percent) with an average age of 37.7 years (range; 17-62 years), mean body weight was 126.5 kg (range; 83-250 kg), mean BMI was 45.7 kg/m2 (range; 33-77 kg/m2) who underwent laparoscopic sleeve gastrectomy for treatment morbid obesity. Postoperative time, 1st day postoperative pain, postoperative complication and postoperative follow up data for the body weight change, percent EWL, BMI and improvement of comorbidity at the 6th, 9th,12th, 18th, and 24th months were recorded. Results: The mean operative time was 75 minutes. The mean operative blood loss was 20 ml. The mean 1st day postoperative pain score was 4. No conversion to laparotomy had to be performed. The mean percentages of excessive body weight loss (EWL) were 46.78 percent at 6 months, 59.75 percent at 1 year, 64.53 percent at 18 months, and 62.92 percent at 2 years. The mean BMI were 35.57 kg/m2 at 6 months, 32.69 kg/m2 at 1 year, 29.23 kg/m2 at 18 months, and 29.45 kg/m2 at 2 years. The rate of resolution of OSA was 65.7 percent and improvement of OSA was 31.4 percent. The rate of resolution of hypertension was 68.9 percent and improvement of hypertension was 31.1 percent. The rate of resolution of DM was 70 percent and improvement of DM was 30 percent. The rate of postoperative complication was 4.2 percent. Conclusions: Laparoscopic sleeve gastrectomy is safe and effective procedure for treatment morbidly obese patients. However, weight regained need to evaluated in long term follow up.

Efficacy analysis of laparoscopic sleeve gastrectomy in treatment of obesity with type 2 diabetes mellitus

To investigate the efficacy and safety of laparoscopic sleeve gastrectomy(LSG) for the treatment of obesity with type 2 diabetes mellitus(T2DM). Clinical data of 32 obesity patients with T2DM patients undergoing LSG from May 2010 to February 2012 in our department were retrospectively analyzed. Their body weight indexes (body weight, waist circumference, BMI, EWL), blood glucose indexes [glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), insulin resistance index (HOMA-IR)], and blood lipid indexes [total cholesterol, triglyceride, low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C)] were measured 1, 3, 6, 12 months after operation and compared with preoperative levels. Improvement in complications was observed. All the patients completed operation under laparoscopy except 1 case because of abdominal cavity adhesion. The average operative time was (115.0±19.6) min, and the average blood loss (69.0±29.7) ml. No operative death, anastomotic leakage, or surgical site infection were found. The body weight, waist circumference and BMI at 1, 3, 6, and 12 months after surgery were significantly lower(all P<0.05) showing a decreasing trend over time. EWL showed significant increasing trend (P<0.05). During 12 months of follow-up, no over-low weight was observed. From 1 month after surgery, HbA1c, FPG and HOMA-IR decreased significantly (P<0.05). HbA1c and FPG maintained stable level at 12 and 6 months after operation respectively. FPG of 28 patients returned to normal 3 months after operation. Clinical complete remission rate of T2DM was 87.5%(28/32), and clinical partial remission rate was 12.5%(4/32) at the 12-month follow-up. Serum total cholesterol, triglyceride and LDL-C decreased obviously after surgery(P<0.05). LSG procedure is a safe and effective surgical method in treatment of obesity with T2DM.

Ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes

Ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes

Ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes

Ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes